Table 2.
Reasons for anakinra start, anakinra dose and route of administration.
| Reason for anakinra prescription | ||
| Worsening of cardiac dysfunctiona | 76.9% | 45.4% |
| Persistent clinical symptomsa | 38.5% | 54.5% |
| Persistent alteration of blood exams abnormalitiesa | 46.2% | 49.9% |
| Anakinra prescription | ||
| Time between admission and anakinra start (days) | 1 (1–2) | 3 (1–7) |
| Iv administration | 100% | 27.3% |
| Sc administration | 0% | 72.7% |
| Mean dose (mg/kg/day) | 8 (6.4–10) | 4 (4–5.2) |
| Duration of anakinra treatment (days, with tapering) | 35 (32–35) | 27 (14–54) |
| First-line therapy | ||
| Patients treated with IVIG (2 g/kg) without corticosteroids | 0% | 0% |
| Patients treated with IVIG (2 g/kg) + corticosteroids (2–30 mg/kg/day iv) | 69.2% | 72.7% |
| Patients treated with corticosteroids (2–30 mg/kg/day iv) | 30.8% | 27.3% |
All the continuous variables are expressed as median and IQR.
a
Multiple choices were possible.